(RTTNews) – Antibe Therapeutics Inc. (ATE. TO, ATBPF. OB) stated that it had put its examination on the absorption, metabolism and excretion or “OMA” of otenaproxesul on a necessary pause because a predefined protection threshold was exceeded.
It is one of many clinical and non-clinical studies conducted prior to the planned phase III program of otenaproxesul.
The SMO study recruited a total of 42 subjects who received a dose of 75 mg or 100 mg of otenaproxesul, 35 of whom had completed the 28-day era of administration of the drug, and seven subjects received the drug for 21 days.
Three subjects in the one hundred mg cohort, who had completed the full era of drug management, had elevations in liver transaminases that exceeded five times the upper limit of normal, triggering the required rupture. normal.
The corporate said it will continue to gather and analyze more knowledge in the coming weeks to perceive the cause and implications of those occasions and the optimal plan for the continued progression of otenaproxesul.